Business

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary

articleYoucare Pharmaceutical Group Co. Ltd. Class AApril 2, 20264/news/announcement-on-voluntary-disclosure-of-obtaining-clinical-trial-approval-from-the-national-medical-products-administration-for-the-indications-for-the-treatment-and-prevention-of-human-bronchovirus-infection-by-the-ykyy018-inhalation-aerosol-of-subsidiary
Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary

About this update from Youcare Pharmaceutical Group Co. Ltd. Class A

Announcement on Voluntary Disclosure of Obtaining Clinical Trial Approval from the National Medical Products Administration for the Indications for the Treatment and Prevention of Human Bronchovirus Infection by the YKYY018 Inhalation Aerosol of Subsidiary The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Youcare Pharmaceutical Group Co. Ltd. Class A